1. Home
  2. AGL vs TRDA Comparison

AGL vs TRDA Comparison

Compare AGL & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo agilon health inc.

AGL

agilon health inc.

HOLD

Current Price

$0.61

Market Cap

422.9M

Sector

Health Care

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$12.60

Market Cap

481.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGL
TRDA
Founded
2016
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Managed Health Care
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
422.9M
481.6M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
AGL
TRDA
Price
$0.61
$12.60
Analyst Decision
Hold
Strong Buy
Analyst Count
14
2
Target Price
$2.66
$20.00
AVG Volume (30 Days)
6.3M
196.5K
Earning Date
01-01-0001
05-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,932,576,000.00
$25,421,000.00
Revenue This Year
N/A
$39.97
Revenue Next Year
$7.17
$53.29
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.34
$4.93
52 Week High
$6.08
$13.99

Technical Indicators

Market Signals
Indicator
AGL
TRDA
Relative Strength Index (RSI) 50.54 55.05
Support Level $0.51 $9.78
Resistance Level $0.73 N/A
Average True Range (ATR) 0.08 0.92
MACD 0.02 0.09
Stochastic Oscillator 64.32 53.40

Price Performance

Historical Comparison
AGL
TRDA

About AGL agilon health inc.

Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: